The estimated Net Worth of Ajit Shetty is at least $131 Thousand dollars as of 28 February 2018. Ajit Shetty owns over 22,730 units of Agile Therapeutics Inc stock worth over $34,322 and over the last 9 years he sold AGRX stock worth over $0. In addition, he makes $97,078 as Independent Director at Agile Therapeutics Inc.
Ajit has made over 2 trades of the Agile Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 22,730 units of AGRX stock worth $9,774 on 28 February 2018.
The largest trade he's ever made was buying 22,730 units of Agile Therapeutics Inc stock on 28 February 2018 worth over $9,774. On average, Ajit trades about 1,858 units every 16 days since 2016. As of 28 February 2018 he still owns at least 22,730 units of Agile Therapeutics Inc stock.
You can see the complete history of Ajit Shetty stock trades at the bottom of the page.
Dr. Ajit S. Shetty Ph.D. serves as Independent Director of the Company. Dr. Shetty spent 36 years at Johnson & Johnson, or J&J, in a wide range of global roles. From 2007 to 2012, he served as Corporate Vice President Enterprise Supply Chain reporting to the Chief Executive Officer and was responsible for the transformation and optimization of J&J's supply chain. Dr. Shetty served as Managing Director of Janssen Pharmaceutica, Belgium from 1999 to 2008, and was part of the management team that grew the Janssen Group of Companies from $1 billion to $8 billion in global sales. Dr. Shetty held the position of Executive Vice President Finance from 1991 to 1999. As President of Janssen Pharmaceutica, U.S. from 1984 to 1990, Dr. Shetty was responsible for in-licensing Durogesic, the first transdermal pain medication, which became the fourth largest J&J product in 2008, with sales reaching $2 billion. In recognition of his unique services as a business leader, Dr. Shetty was awarded the Right Honourable Sir and Title of Baron by King Albert II of Belgium in 2008 and the Life-Time Achievement Award by India in 2010. He was elected "Manager of the Year 2004" by the magazine Trends and Kanaal Z. Dr. Shetty serves as a Trustee of Carnegie Mellon University and has served on the corporate Advisory Board of Johns Hopkins Carey School of Business, the Board of Governors for GS1 (Global Standards), the Board of MCB Forum as Chairman, and the Supervisory Board of Cilag GMBH in Switzerland. He earned a Ph.D. in Metallurgy and B.A. Natural Sciences from Trinity College, Cambridge University and a Master of Business Administration from Carnegie Mellon University. Shetty's qualifications to sit on our Board of Directors include his extensive pharmaceutical experience leading commercial and supply chain operations and his significant education background.
As the Independent Director of Agile Therapeutics Inc, the total compensation of Ajit Shetty at Agile Therapeutics Inc is $97,078. There are 10 executives at Agile Therapeutics Inc getting paid more, with Alfred Altomari having the highest compensation of $1,301,370.
Ajit Shetty is 73, he's been the Independent Director of Agile Therapeutics Inc since 2016. There are no older and 18 younger executives at Agile Therapeutics Inc.
Ajit's mailing address filed with the SEC is C/O ACTINIUM PHARMACEUTICALS, INC.,, 100 PARK AVE., 23RD FLOOR, NEW YORK,, NY, 10017.
Over the last 10 years, insiders at Agile Therapeutics Inc have traded over $2,369,944 worth of Agile Therapeutics Inc stock and bought 24,967,253 units worth $79,522,957 . The most active insiders traders include Advisors Llcperceptive Life..., Ab Investor, and Capital Iii Llc Care Capita.... On average, Agile Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $1,032,678. The most recent stock trade was executed by Alfred Altomari on 26 August 2022, trading 50,000 units of AGRX stock currently worth $22,500.
agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.
Agile Therapeutics Inc executives and other stock owners filed with the SEC include: